ZGZhen Guo

Zhen Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhen Guo has a total of 128 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Javaheri

    Washington University School of Medicine, St. Louis, MO (D.L.M., A.J.).

    8 shared publications
  • Carla Valenzuela Ripoll

    Department of Medicine, Division of Cardiology, Washington University School of Medicine in St Louis, Saint Louis, Missouri, USA

    4 shared publications
  • Attila Kovacs

    Washington University School of Medicine, United States

    3 shared publications
  • Joel D. Schilling

    Division of Cardiology, Washington University in St. Louis, St. Louis MO USA

    3 shared publications
  • Alireza Sargazi

    Department of Medicine, Division of Cardiology (Z.G., A.Ataran, P.M., Y.W., H.H., C.V.R., L.N.P., O.R., M.M.C., M.Shen, A.S., M.O., A.L., Y.C., A.D., A.P., A.I., R.L., A.B.Z., A.Kovacs, S.D.P., J.D.S., K.J.L., A.J.), Washington University School of Medicine, St Louis, MO

    2 shared publications
  • Anahita Ataran

    Department of Medicine, Division of Cardiology (Z.G., A.Ataran, P.M., Y.W., H.H., C.V.R., L.N.P., O.R., M.M.C., M.Shen, A.S., M.O., A.L., Y.C., A.D., A.P., A.I., R.L., A.B.Z., A.Kovacs, S.D.P., J.D.S., K.J.L., A.J.), Washington University School of Medicine, St Louis, MO

    2 shared publications

Latest Publications

  • Open Access

    Apolipoprotein M in Right Heart Failure

    by Mahmoud I Elesawy, Christina F Fu, Adeesh Parvathaneni, Arick C Park, Zhen Guo, Jason Liu, Christina Christoffersen, Carla J Weinheimer, Attila Kovacs, Jessica Nigro, et al.

    Background: Right heart failure (RHF) leads to an elevation in central venous pressure and causes hepatic congestion. Apolipoprotein M (ApoM), a hepatocyte-derived lipocalin bound to high-density lipoprotein, transports sphingosine-1-phosphate (S1P), which maintains vascular integrity and modulates inflammation. Although low ApoM predicts adverse outcomes in heart failure (HF), its role in RHF is unclear. We sought to investigate the impact of RHF on circulating ApoM, its prognostic value in RHF mortality, and its functional role in the cardio-hepatic axis. Methods: Patients undergoing right heart catheterization were classified as normal, HF, or RHF. Serum ApoM and S1P were measured by ELISA. Survival was analyzed using Kaplan–Meier and Cox proportional hazards models. Meanwhile, ApoM Tg or WT mice were subjected to pulmonary artery banding (PAB) to induce right ventricular (RV) dysfunction or partial inferior vena cava ligation (pIVCL) to cause hepatic congestion. Cardiac and hepatic pathology were assessed by tissue imaging and molecular analyses. Results: ApoM levels were lowest in RHF patients and inversely correlated with inflammatory markers. Each 0.01 μM increase in ApoM was associated with a 6% lower risk of mortality. PAB induced RV dysfunction and reduced serum ApoM in wild-type mice, while ApoM Tg mice showed less severe RV remodeling and improved hepatic congestion. In contrast, ApoM Tg mice subjected to pIVCL showed no significant improvement in liver pathology. Conclusion: In patients with RHF and mice with RV dysfunction, circulating ApoM was reduced. Lower ApoM was independently associated with worse outcomes. Restoring ApoM expression primarily protects the heart and subsequently alleviates liver congestion, underscoring its distinct protective role in the heart–liver axis. Further investigation of the ApoM axis in RHF is warranted. Disclosures: Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR002344. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Graphical

  • Low-Dose Cardiac Radiation Improves Electrical Function and Reduces Ventricular Arrhythmogenesis in Mice With Nonischemic Cardiomyopathy

    by Devaki A. Abhyankar, Marissa R. Pennino, Lauren N. Pedersen, Felicia Grogan, Amanda Klass, Carla Valenzuela Ripoll, Sherwin Ng, Zhen Guo, Hamidreza Hajirezaei, Stacey L. Rentschler, et al.


  • Open Access

    Induction of TFEB promotes Kupffer cell survival and reduces lipid accumulation in MASLD

    by Mandy M. Chan, Sabine Daemen, Wandy Beatty, Kathleen Byrnes, Kevin Cho, Daniel Ferguson, Natalie Feldstein, Christopher Park, Zhen Guo, Arick C. Park, et al.

    Background: Kupffer cells (KCs) are the tissue-resident macrophages of the liver, where they serve a critical role in maintaining liver tissue homeostasis and act as a filter for circulation. The composition of hepatic macrophages changes during metabolic dysfunction–associated liver disease (MASLD), with the loss of resident KCs being a hallmark of disease progression. The mechanism(s) and consequences of KC death in metabolic liver disease have yet to be defined. Transcription factor EB (TFEB) is a master regulator of lysosome function and lipid metabolism, which has been shown to protect macrophages from lipid stress in atherosclerosis. We hypothesized that TFEB would improve KC fitness in MASLD. Methods: To investigate the potential beneficial effect of TFEB induction in KCs, we created a transgenic mouse in which TFEB was overexpressed specifically in KCs and evaluated its impact on disease pathogenesis in high-fat, high-sucrose (HFHS) and choline-deficient diet models of MASLD. Results: We found that TFEB induction protected KCs from cell death in both models of MASLD. KC preservation through TFEB induction reduced liver steatosis with HFHS diet via mechanisms that were dependent on macrophage lysosomal lipolysis and mitochondrial fatty acid oxidation. Fibrosis was unchanged in choline-deficient diet studies. TFEB protected KCs from cell death by diminishing oxidative stress and reducing ferroptosis through a mechanism that involved enhanced NADPH levels. Conclusions: TFEB induction promotes KC fitness upon lipid stress during MASLD. Preservation of lipid-adapted KCs demonstrates beneficial effects against liver steatosis and protects portal filtration during MASLD.


  • Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy

    by Zhen Guo, Anahita Ataran, Pan Ma, Wenjing Yu, Hamidreza Hajirezaei, Carla Valenzuela Ripoll, Lauren N. Pedersen, Omid Rashidi, Mandy M. Chan, Mengcheng Shen, et al.

    BACKGROUND: Doxorubicin cardiomyopathy (DoxCM) remains a significant clinical problem, but its underlying mechanisms remain incompletely understood. Identifying DoxCM mechanisms can lead to therapeutic interventions that improve patient outcomes. METHODS: We performed single-nucleus RNA sequencing on left ventricular myocardial tissue from patients with DoxCM versus nonischemic cardiomyopathy and nonfailing donors. This approach aimed to uncover the transcriptional changes associated with DoxCM. Additionally, we conducted immunostaining, flow cytometry, antibody neutralization, and cell depletion studies to validate our findings and define in vivo mechanisms. RESULTS: Compared with nonfailing donors and patients with nonischemic cardiomyopathy, left ventricular myocardium from patients with DoxCM exhibited increased POSTN (periostin) + activated fibroblasts, downregulation of genes involved in phagocytosis, and increased expression of the antiphagocytic molecule CD47. Immunostaining of human cardiac sections and murine studies demonstrated increased POSTN + cells and CD47 in DoxCM and in a murine breast cancer model. CD47 antibody neutralization both prevented and treated doxorubicin-induced reduction in left ventricular ejection fraction and fibrosis. Mechanistically, depletion of resident cardiac macrophages blocked the cardioprotective effects of CD47 neutralization and clearance of cardiac fibroblasts. CONCLUSIONS: Our data support CD47 as a disease-specific target and promising therapeutic approach for mitigating cardiac dysfunction in DoxCM.


  • GPLD1 Attenuates Heart Failure via Dual-Membrane Localization to Inhibit uPAR

    by Wenjing Yu, Zhen Guo, Huimin Liang, Dinghu Ma, Chenjia Lin, Zeyu Li, Jiaying Yu, Anahita Ataran, Ali Javaheri, Zhiping Liu, et al.

    BACKGROUND: Despite the established role of GPLD1 (glycosylphosphatidylinositol-specific phospholipase D1) in age-related impairments, its involvement in cardiovascular diseases remains unclear. METHODS: We analyzed GPLD1 transcript and protein levels in heart tissues from patients with heart failure (HF) and murine HF models. Genetic approaches, including cardiac-specific depletion, overexpression, or mutation of GPLD1, alongside intramyocardial injection of adeno-associated virus 9–mediated GPLD1 overexpression or its short hairpin RNA transduction, were used to assess the functional role of GPLD1 in transverse aortic constriction–induced HF mouse models. Proteomic profiling identified candidate binding targets, which were validated using methods including proximity ligation assay and coimmunoprecipitation. uPAR (urokinase-type plasminogen activator receptor) overexpression or short hairpin RNA targeting uPAR was performed to interrogate mechanistic pathways. Subcellular localization of GPLD1 was investigated through membrane lipid analysis and subcellular fractionation of plasma membrane and mitochondrial compartments. Cardiomyocytes were transfected with pRS426GFP-2×PH (PLC [phospholipase C] δ) to monitor phosphatidylinositol 4,5-bisphosphate levels. Cytosolic and mitochondrial calcium levels, mitochondrial permeability transition pore opening, and oxygen consumption rate were measured to evaluate cellular homeostasis and bioenergetics. RESULTS: GPLD1 levels were elevated in patients with HF and murine models. Cardiac-specific GPLD1 depletion exacerbated cardiac dysfunction and hypertrophy, while its overexpression ameliorated these effects, depending on enzymatic activity. uPAR was identified as a potential binding target for GPLD1, and viral-mediated uPAR transduction completely abolished the protective effects of GPLD1 following transverse aortic constriction surgery. Mechanistically, GPLD1 was anchored to the plasma membrane and outer mitochondrial membrane via phosphatidylinositol 4,5-bisphosphate to cleave the glycosylphosphatidylinositol anchor of uPAR, thereby maintaining calcium homeostasis and mitochondrial function, and ultimately ameliorating cardiac dysfunction. Conversely, excess uPAR led to a decrease in phosphatidylinositol 4,5-bisphosphate levels, preventing GPLD1 from localizing to these membranes and causing it to disperse in the cytoplasm. CONCLUSIONS: Our studies identify GPLD1 as an endogenous protective factor against HF and suggest that it may be a promising therapeutic target for cardiac dysfunction and HF.


  • Open Access

    Sodium-Glucose Cotransporter Inhibition Preserves Apolipoprotein M During Acute Inflammation in Mice and Humans

    by Carla Valenzuela Ripoll, Aynaz Lotfinaghsh, Zhen Guo, Tripti Kumari, Kana N. Miyata, Alireza Sargazi, Mualla Ozcan, Ahmed Diab, Anahita Ataran, Hamidreza Hajirezaei, et al.


  • Open Access

    Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients

    by Andrew J. Sauer, Joycie Chang, Zhuxuan Fu, Carla Valenzuela Ripoll, Yoonje Cho, Zhen Guo, Philip Jones, Senthil Selvaraj, Sheryl L. Windsor, Mansoor Husain, et al.


  • Open Access

    Apolipoprotein M attenuates age-related macular degeneration phenotypes via sphingosine-1-phosphate signaling and lysosomal lipid catabolism

    by Tae Jun Lee, Andrea Santeford, Kristen M. Pitts, Carla Valenzuela Ripoll, Ryo Terao, Zhen Guo, Mualla Ozcan, Dagmar Kratky, Christina Christoffersen, Ali Javaheri, et al.

    Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50. AMD and cardiovascular disease share risk factors including age, impaired lipid metabolism, and extracellular lipid deposition. Because of its importance in age-related diseases, we hypothesize that apolipoprotein M (ApoM), a lipocalin that binds sphingosine-1-phosphate (S1P), might restore lipid homeostasis and retinal function in AMD. In support, we find that human patients with AMD demonstrate significantly reduced ApoM compared to controls. In mice with impaired retinal cholesterol efflux, ApoM improves retinal pigment epithelium (RPE) function and lipotoxicity in an S1P- and S1P receptor 3-dependent manner. Ultrastructural evidence of enhanced melanosome-lipid droplet interactions led us to hypothesize and demonstrate that ApoM-S1P signaling drives RPE-specific lysosomal lipid catabolism. RPE-specific knockout of lysosomal acid lipase recapitulates features of AMD. Our study defines a novel role for ApoM/S1P signaling in AMD driven by RPE lipotoxicity, mediated by cell-autonomous lysosomal lipid catabolism.


  • Open Access

    Empagliflozin to Prevent Doxorubicin Cardiotoxicity

    by Zhen Guo, Ali Javaheri